A global clinical trial successfully reduced toxicity and side effects in advanced stage Hodgkin lymphoma patients by using a modified treatment regimen.
Mark Herzberg is a Professor of Clinical Haematology involved in clinical trials for patients with blood cancers, particularly lymphoma, leukaemia, and myeloma, in Australia and New Zealand.
Hodgkin lymphoma is a common cancer with varied symptoms, and treatment typically involves chemotherapy and sometimes radiation therapy.
Approximately 800 Australian patients are diagnosed with advanced stage Hodgkin lymphoma each year, with staging determined through imaging and blood tests.
Advanced stage Hodgkin lymphoma is treated with outpatient combination chemotherapy using two major regimens (ABVD and escalated BEACOPP) worldwide, with a global clinical trial involving nine cooperative groups in nine countries and 1500 patients.
The ALLG contributed 115 patients across 16 sites in Australia and New Zealand to a groundbreaking clinical trial.
A global clinical trial successfully reduced toxicity and side effects in advanced stage Hodgkin lymphoma patients by using a modified treatment regimen incorporating a new drug, Brentuximab Vedotin.
Patients experienced fewer side effects, such as anaemia, low platelet counts, peripheral neuropathy, and gonadal toxicity, while preserving fertility, with the modified BrECADD regimen in the treatment of advanced stage Hodgkin lymphoma.
Most patients with advanced stage Hodgkin lymphoma remained disease-free after three years of treatment, with a significant reduction in toxicity and shorter duration of treatment, allowing them to resume normal life and work sooner.
Australian Health Journal spoke with Professor Mark Hertzberg in his role in the ALLG HD10 Clinical Trial and as a former Chair of the Scientific Advisory Committee of the Australasian Leukaemia & Lymphoma Group (ALLG), an organisation involved in improving the treatments and lives of blood cancer patients.
You Might also like
-
Belonging in a medical device company
Edith de Boer is the HR Director for Zimmer Biomet in Australia and New Zealand. Her career originally was in telecommunications and consulting in Europe. After leaving The Netherlands, Edith worked into the Australian medical research industry, before moving into a human resources role at Zimmer Biomet. Edith spoke to Australian Health Journal about her role and the organisation.
-
Dentist creates app to democratise oral health care
In this People In Health Care segment, Dr Gadiyar spoke to Australian Health Journal on how she hopes the app will help increase the number of people seeking dental treatment from the current 47% level in Australia. To date, 120,000 users have downloaded the app with more than 50 dental practices signed up with Smilo.ai to receive individual enquiries or seek dental treatment.
-
Ensuring stringent quality standards in the lifecycle of medical devices
Dr Jasjit Baveja is the Associate Director of Policy at the Medical Technology Association of Australia (MTAA), where she oversees regulatory affairs, clinical code of practice, procurement, industry policy, reimbursement, and advocacy. With over 20 years of experience in the medical device regulatory space, Dr Bavej’s expertise lies in providing educational opportunities for regulatory professionals in Australia to ensure continuous learning and professional development. She collaborates closely with the Therapeutic Goods Administration (TGA) to run workshops that provide invaluable experience, networking opportunities, and skill enhancement.